Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-4,page-paged-4,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • ABIVAX PHASE 3 PROGRAM WITH OBEFAZIMOD IN ULCERATIVE COLITIS PROGRESSES WITH US IRB APPROVAL
    04 August 2022
    www.abivax.com
  • QUANTRO Therapeutics collaborates with Boehringer Ingelheim to develop drug candidates interfering with transcriptional regulators
    03 August 2022
    www.quantro-tx.com
  • Spexis provides business update
    28 July 2022
    www.spexisbio.com
  • Destiny Pharma: Chair’s Investor Update
    28 July 2022
    www.destinypharma.com
  • Destiny Pharma: Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections
    26 July 2022
    www.destinypharma.com
  • Marinomed to pause issuing of tranches of Convertible Notes Funding Program to Nice & Green
    21 July 2022
    www.marinomed.com
  • iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members
    20 July 2022
    www.iomx.com
  • Spexis announces business update call to be held on July 28th
    20 July 2022
    www.spexisbio.com
  • CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients
    13 July 2022
    www.cevec.com
  • Adrenomed appoints David Germonpré as Chief Financial Officer
    12 July 2022
    www.adrenomed.com